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Abstract
Aripiprazole is a second-generation antipsychotic that is increasingly being prescribed to children 
and adolescents. Despite this trend, little preclinical research has been done on the neural and 
behavioral actions of aripiprazole during early development. In the present study, young male and 
female Sprague-Dawley rats were pretreated with vehicle, haloperidol (1 mg/kg), or aripiprazole 
(10 mg/kg) once daily on postnatal days (PD) 10–20. After one, four, or eight days (i.e., on PD 21, 
PD 24, or PD 28), amphetamine-induced locomotor activity and stereotypy, as well as dorsal 
striatal D2 receptor levels, were measured in separate groups of rats. Pretreating young rats with 
aripiprazole or haloperidol increased D2 binding sites in the dorsal striatum. Consistent with these 
results, dopamine supersensitivity was apparent when aripiprazole- and haloperidol-pretreated rats 
were given a test day injection of amphetamine (2 or 4 mg/kg). Increased D2 receptor levels and 
altered behavioral responding persisted for at least eight days after conclusion of the pretreatment 
regimen. Contrary to what has been reported in adults, repeated aripiprazole treatment caused D2 
receptor up-regulation and persistent alterations of amphetamine-induced behavior in young rats. 
These findings are consistent with human clinical studies showing that children and adolescents 
are more prone than adults to aripiprazole-induced side-effects, including extrapyramidal 
symptoms.
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Introduction
Aripiprazole is a second-generation antipsychotic that is commonly used to treat 
schizophrenia in adult humans. Aripiprazole is purported to reduce both positive and 
negative symptoms, while exhibiting a good side-effect profile (for reviews, see Stip and 
Tourjman, 2010; Croxtall, 2012). Although aripiprazole is most typically categorized as a 
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dopamine (DA) D2 partial agonist or as a functionally selective D2 ligand (Burris et al., 
2002; Urban et al., 2007; Koener et al., 2012), this compound is also a partial agonist at 
serotonin 5-HT1A receptors (Jordan et al., 2002; Shapiro et al., 2003), a full antagonist at 5-
HT2A receptors (Jordan et al., 2004), and it alters the expression of GABAergic binding sites 
and glutamatergic transporters (Segnitz et al., 2011; Peselmann et al., 2013). All of these 
actions have potential therapeutic impact because serotonergic, GABAergic, and 
glutamatergic dysfunction has been linked to schizophrenia (for reviews, see Benes and 
Berretta, 2001; Stone et al., 2007; Meltzer et al., 2011). Nonetheless, most of aripiprazole’s 
therapeutic effects have been ascribed to its ability to normalize dopaminergic functioning 
(Burris et al., 2002; Zocchi et al., 2005).
The low propensity of aripiprazole for inducing side-effects, including extrapyramidal motor 
movements, may be due to an absence of modifications at the DA D2 receptor [Table 1 near 
here]. Regardless of route of administration, treatment duration, or dose (see Table 1), 
researchers have reported that repeated aripiprazole treatment neither up-regulates D2 
receptors in adult rats (Inoue et al., 1997; Seeman, 2008; Tadokoro et al., 2012) nor causes 
DA supersensitivity (Tadokoro et al., 2012). Instead, aripiprazole appears to normalize the 
D2 receptor up-regulation and behavioral supersensitivity caused by daily haloperidol 
administration (Tadokoro et al., 2012). The one exception to this general pattern was 
reported by Seeman (2008), who found that a one-week regimen of aripiprazole significantly 
increased the ratio of D2High receptors in adult rat striatum, an outcome that is often 
associated with DA supersensitivity (Seeman et al., 2005).
World-wide, aripiprazole is increasingly being administered to children and adolescents, 
with many of its prescribed uses being off-label (McKinney and Renk, 2011). Among 
pediatric populations, aripiprazole has received FDA approval for the treatment of Bipolar I 
disorder (ages 10–17) and schizophrenia (ages 13–17); however, aripiprazole is also reported 
to be of therapeutic benefit for the treatment of autism and other pervasive developmental 
disorders (Stachnik and Nunn-Thompson, 2007; Masi et al., 2009; Stigler et al., 2009), 
aggression and conduct disorder (Bastiaens, 2009; Findling et al., 2009a), as well as 
Tourette’s syndrome and chronic tic disorder (Seo et al., 2008; Murphy et al., 2009; Yoo et 
al., 2011). While there are an abundance of studies assessing the efficacy and side-effect 
profiles of aripiprazole in children and adolescent patients (Fraguas et al., 2011; Kirino, 
2012), very few preclinical studies have examined the effects of repeated aripiprazole 
treatment using developmental animal models. Most notably, Der-Ghazarian et al. (2010) 
reported that an 11-day regimen of aripiprazole (10 mg/kg once daily) administered to rats 
on postnatal day (PD) 10–20 caused a short-term decline in the sensitivity of synthesis-
modulating autoreceptors. This decrease in autoreceptor sensitivity was apparent one day, 
but not three days, after conclusion of the drug pretreatment regimen, and was similar to the 
pattern of effects produced by the D2 receptor antagonist haloperidol. When measured on 
PD 24 (i.e., three days after conclusion of the pretreatment regimen), repeated aripiprazole 
treatment produced a nonsignificant 35% elevation in dorsal striatal D2 binding sites when 
compared to control rats (Der-Ghazarian et al., 2010). To our knowledge, no studies have 
examined the effects of repeated aripiprazole treatment on the functioning of postsynaptic 
D2 receptors during early ontogeny.
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The purpose of the present study was to determine whether repeated administration of 
aripiprazole causes DA supersensitivity in young rats. As mentioned above, Tadokoro et al. 
(2012) reported that aripiprazole does not cause supersensitivity in adult rats; however, it is 
well established that young and adult animals often respond in a qualitatively different 
manner after repeated treatment with DA-acting drugs (for reviews, see Spear, 1979; Tirelli 
et al., 2003; Andersen, 2005). For this reason, young rats were treated with aripiprazole (10 
mg/kg) on PD 10–20 and behavioral responsiveness to a challenge injection of saline or 
amphetamine (2 or 4 mg/kg) was assessed one, four, or eight days later (i.e., on PD 21, PD 
24, or PD 28). For comparison purposes, separate groups of young rats were pretreated with 
the D2 antagonist haloperidol on PD 10–20. Horizontal locomotor activity and stereotyped 
sniffing were quantified across a 120 min testing period. Sniffing was assessed because this 
discrete behavior is a very reliable measure of moderately intense stereotypy in young rats 
(Cortez et al., 2010; Charntikov et al., 2011); whereas, locomotor activity is typically viewed 
as a nonstereotyped behavior that, under certain circumstances, may include a transient low-
intensity stereotypy component (Segal and Kuczenski, 1987; Mueller et al., 1989; for a 
review, see Arnt, 1987). Therefore, by quantifying sniffing and locomotor activity we were 
able to determine the impact of repeated aripiprazole administration on both a stereotyped 
and nonstereotyped behavior. To examine D2 receptor up-regulation, homogenate ligand 
assays were used to measure D2 receptor densities in the dorsal striatum of aripiprazole- and 
haloperidol-pretreated rats on PD 21, PD 24, and PD 28.
Methods and Materials
Subjects
Subjects were 306 male and female rats of Sprague-Dawley descent (Charles River, 
Hollister, CA, USA) that were born and bred in the university vivarium. Litters were culled 
to ten pups at PD 3 (day of parturition is PD 0) and weaned at PD 25. Both preweanling and 
postweanling rats were housed on racks in large polycarbonate maternity cages (56 × 34 × 
22 cm) with wire lids. Food and water were freely available. The colony room was 
maintained at 22–24°C and kept under a 12/12 h light/dark cycle. Behavioral testing was 
conducted in a separate experimental room during the light phase of the cycle. Subjects were 
cared for according to the “Guide for the Care and Use of Laboratory Animals” (National 
Research Council, 2010) under a research protocol approved by the university’s Institutional 
Animal Care and Use Committee.
Apparatus
Behavioral testing was done in activity monitoring chambers (25.5 × 25.5 × 41 cm) that 
consisted of acrylic walls, a plastic floor, and an open top (Coulbourn Instruments, 
Allentown, PA, USA). Each chamber included an X–Y photobeam array, with 16 photocells 
and detectors, that was used to determine distance traveled (a measure of horizontal 
locomotor activity). Photobeam resolution was 0.76 cm, with the position of each rat being 
determined every 100 ms.
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Drugs
D-Amphetamine hemisulfate salt was dissolved in saline, whereas haloperidol was dissolved 
in a minimal amount of glacial acetic acid and diluted with saline. Aripiprazole was 
dissolved in (2-hydropropyl)-β-cyclodextrin solution (HBC, 45% (w/v) solution in water). 
All drugs were injected intraperitoneally (i.p.) at a volume of 2.5 ml/kg. With the exception 
of aripiprazole (Toronto Research Chemicals, Toronto, Canada), all nonlabeled ligands were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). [3H]-spiperone (83.9 Ci/mmol) was 
purchased from PerkinElmer (Boston, MA, USA).
Behavioral Testing
On PD 10–20, young male and female rats (N = 216) were given daily pretreatment 
injections of saline vehicle, HBC vehicle, aripiprazole (10 mg/kg, i.p.), or haloperidol (1 
mg/kg, i.p.). Behavioral testing occurred one, four, or eight days later (i.e., on PD 21, PD 24, 
or PD 28). Separate groups of rats were tested at each age to preclude sensitization effects. 
On the test day, rats (n = 8 per group) were injected with saline or D-amphetamine (2 or 4 
mg/kg, i.p.) and immediately placed in activity monitoring chambers for 120 min (divided 
into six 20-min time blocks).
Distance traveled was assessed continuously across the testing session. In addition to this 
automated measure, behavior was recorded via ceiling-mounted hard disk cameras (JVC, 
model GZ-MG670) and data were later coded by observers blind to treatment conditions. 
Discrete behaviors (e.g., sniffing, vertical activity, and licking) were quantified using the 
fixed interval momentary time sampling method described by Cameron et al. (1988). Using 
this technique, the presence or absence of a particular behavior was determined at 20 s 
intervals during each 20-min time block. Behaviors of the saline- and HBC-treated rats did 
not differ, therefore data from the two vehicle groups were combined for presentation and 
statistical purposes.
D2 Homogenate Ligand Binding Assays
On PD 10–20, young male and female rats (N = 90) were given daily pretreatment injections 
of saline vehicle, HBC vehicle, aripiprazole (10 mg/kg, i.p.), or haloperidol (1 mg/kg, i.p.). 
After one, four, or eight days (i.e., on PD 21, PD 24, or PD 28), rats (n = 10 per group) were 
killed by rapid decapitation and dorsal striatal sections were dissected bilaterally on an ice-
cold dissection plate and stored at –80°C. On the day of assay, tissue was thawed on ice and 
striatal samples were homogenized in 100 volumes of 50 mM Tris-HCl buffer (pH 7.4) for 
approximately 20 s using a Brinkmann Polytron. Homogenates were then centrifuged at 
20,000 × g for 20 min. The pellet was resuspended in 100 volumes of the same buffer and 
centrifuged again at 20,000 × g for 20 min. The final pellet was suspended in approximately 
30 volumes of buffer (pH 7.4). Protein concentrations for the final pellet were determined 
using the Bio-Rad Protein Assay.
Tissue suspensions were added to duplicate tubes containing 50 mM Tris, 2 mM NaCl2, 5 
mM KCl, 1 mM MgSO4, and 2 mM CaCl2 (pH 7.4) at a final volume of 1 ml. The tubes also 
included [3H]-spiperone in concentrations ranging from 0.007 to 3.5 nM. Nonspecific 
binding was determined in the presence of 10 μM (–)-sulpiride. Incubation time for both 
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assays was 30 min at 37°C. Incubation was terminated by vacuum filtration over glass fiber 
filters (Whatman GF/B, pretreated with 0.1% polyethylenimine). Filters were washed twice 
with ice-cold Tris-HCl buffer and radioactivity was measured by liquid scintillation 
spectrometry.
Data Analysis
Litter effects were minimized by assigning no more than one subject from each litter to a 
particular group (for a discussion of litter effects, see Zorrilla, 1997). When this procedure 
was not possible (i.e., analysis of body weights), a single litter mean was calculated from 
multiple littermates assigned to the same group (Holson and Pearce, 1992; Zorrilla, 1997). 
Whenever possible, litter effects were also controlled through statistical procedures. 
Specifically, no more than one subject from each litter was assigned to a particular group 
and litter was used as the unit of analysis for statistical purposes (Zorrilla, 1997). With this 
statistical model each litter, rather than each rat, is treated as an independent observation 
(i.e., a within analysis using one value/condition/litter).
Body weight data on PD 21, PD 24, and PD 28 were analyzed using separate two-way 
(Pretreatment Condition × Sex) analyses of variance (ANOVA) at each test day. For the 
behavioral experiments, distance traveled and sniffing data were analyzed using three-way 
(Pretreatment Condition × Test Drug × Time Block) ANOVAs for each test day. Statistically 
significant three-way interactions were supplemented by separate two-way ANOVAs 
(Pretreatment Condition × Time Block) that were conducted for each test drug. For the 
ligand binding experiment, D2 binding sites (Bmax) and affinity (KD) were determined using 
nonlinear regression with Prism (GraphPad Software, San Diego, CA, USA). Bmax and KD 
values were analyzed using two-way (Pretreatment Condition × Recovery Interval) 
ANOVAs. When the assumption of sphericity was violated, as determined by Mauchly’s test 
of sphericity, the Huynh-Feldt epsilon statistic was used to adjust the degrees of freedom 
(Huynh and Feldt, 1976). Corrected degrees of freedom were rounded to the nearest whole 
number and are indicated by a superscripted “a”. Prepubescent rats, unlike young mice 
(Laviola et al., 1994), do not typically exhibit sex differences after DA agonist treatment 
(Frantz et al., 1996; Bowman et al., 1997; Snyder et al., 1998; Der-Ghazarian et al., 2012). 
Consistent with these past rat studies, distance traveled data did not differ according to sex, 
so this variable was not included in the final statistical analyses. Tukey tests (p < 0.05) were 
used for making post hoc comparisons.
Results
Body Weights
When measured on PD 21 and PD 24 (1 or 4 days after conclusion of the pretreatment 
regimen), body weights of aripiprazole- and haloperidol-pretreated rats were significantly 
reduced relative to the vehicle controls (Table 2) [Pretreatment Condition main effects, 
F(2,14)= 13.18, p < 0.01; F(2,14)= 8.89, p < 0.01, respectively]. Pretreatment regimen did not 
significantly affect body weights on PD 28 [Table 2 near here]. Overall, male rats weighed 
more than female rats on all three test days (i.e., PD 21, PD 24, and PD 28) [Sex main 
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effects, F(1,7)= 10.25, p < 0.05; F(1,7)= 9.76, p < 0.05; F(1,7)= 44.51, p < 0.001, respectively]. 
At no age did the pretreatment variable interact with sex to affect body weight.
Behavioral Effects of Aripiprazole and Haloperidol Pretreatment
Locomotor Activity—Regardless of test day (PD 21, PD 24, or PD 28), rats treated with 2 
mg/kg D-amphetamine exhibited more locomotor activity than saline-treated rats, with 4 
mg/kg D-amphetamine producing an intermediate level of locomotion that was significantly 
different from the other two groups [Test Drug main effects, F(2,14)= 124.16, p < 0.001; 
F(2,14)= 198.23, p < 0.001; F(2,14)= 98.07, p < 0.001, respectively].
When assessed one day after conclusion of the pretreatment phase (i.e., on PD 21), 
aripiprazole and haloperidol did not affect the locomotor activity of rats given saline or 2 
mg/kg D-amphetamine (Figure 1) [Figure 1 near here]. When given a test day injection of 4 
mg/kg D-amphetamine, haloperidol-pretreated rats exhibited less locomotor activity than 
vehicle controls on time blocks 2, 3, 5, and 6; whereas, aripiprazole-treated rats exhibited 
less locomotor activity than the vehicle group on time blocks 5 and 6 [aPretreatment 
Condition × Test Drug × Time Block interaction, F(16,113)= 1.78, p < 0.05; supplemented 
by aPretreatment Condition × Time Block interaction, F(10,67)= 6.30, p < 0.001; Pretreatment 
Condition main effect, F(2,14)= 5.32, p < 0.05].
An almost identical pattern of behavior occurred when rats were tested four days after 
conclusion of the drug pretreatment regimen (i.e., on PD 24). Neither aripiprazole nor 
haloperidol pretreatment affected the test day performance of rats injected with saline or 2 
mg/kg D-amphetamine (Figure 2) [Figure 2 near here]. On the other hand, haloperidol-
pretreated rats given a test day injection of 4 mg/kg D-amphetamine exhibited less locomotor 
activity than vehicle controls on time blocks 2, 3, 5, and 6 [Pretreatment Condition × Test 
Drug × Time Block interaction, aF(14,95)= 3.58, p < 0.001; supplemented by aPretreatment 
Condition × Time Block interaction, F(4,30)= 6.54, p < 0.001; Pretreatment Condition main 
effect, F(2,14)= 5.71, p < 0.05]. On time blocks 5 and 6, aripiprazole-pretreated rats injected 
with 4 mg/kg D-amphetamine locomoted less than vehicle-pretreated rats given the identical 
dose of D-amphetamine.
When assessed eight days after conclusion of the pretreatment phase (i.e., on PD 28), 
aripiprazole and haloperidol pretreatment did not differentially affect performance of rats 
given saline or 2 mg/kg D-amphetamine (Figure 3) [Figure 3 near here]. In contrast, 
aripiprazole- and haloperidol-pretreated rats given a test day injection of 4 mg/kg D-
amphetamine exhibited less locomotor activity on time blocks 2–6 than vehicle controls 
injected with an identical dose of D-amphetamine [aPretreatment Condition × Test Drug × 
Time Block interaction, F(13,92)= 2.25, p < 0.05; supplemented by aPretreatment Condition × 
Time Block interaction, F(6,43)= 4.63, p < 0.001; Pretreatment Condition main effect, 
F(2,14)= 9.80, p < 0.01].
Sniffing—On all test days (PD 21, PD 24, and PD 28), amphetamine caused a dose-
dependent increase in stereotyped sniffing [Test Drug main effects, F(2,14)= 74.38, p < 0.001; 
F(2,14)= 108.00, p < 0.001; F(2,14)= 120.69, p < 0.001, respectively]. On PD 21 [Figure 4 
near here], rats pretreated with either aripiprazole or haloperidol had significantly greater 
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sniffing counts than rats exposed to vehicle (Figure 4) [Pretreatment Condition main effect, 
F(2,14)= 7.54, p < 0.01]. On PD 24 [Figure 5 near here], only haloperidol-pretreated rats had 
more sniffing counts than vehicle controls (Figure 5) [Pretreatment Condition main effect, 
F(2,14)= 5.09, p < 0.05].
When assessed eight days after conclusion of the pretreatment phase (i.e., on PD 28), 
pretreatment regimen did not affect the stereotyped sniffing of rats injected with saline or 2 
mg/kg amphetamine (Figure 6) [Figure 6 near here]. In contrast, haloperidol-, but not 
aripiprazole-, pretreated rats exhibited significantly more stereotyped sniffing counts than 
vehicle controls when challenged with 4 mg/kg amphetamine [Pretreatment Condition × 
Test Drug interaction, F(4,28)= 6.54, p < 0.01; supplemented by Pretreatment Condition main 
effect, F(2,14)= 8.09, p < 0.01].
D2 Receptor Binding in the Dorsal Striatum
Overall, both aripiprazole and haloperidol increased D2 binding site densities (i.e., Bmax 
values) in the dorsal striatum (Table 3) [Pretreatment Condition main effect, F(2,54)= 7.54, p 
< 0.001]. This effect was not restricted to a single day, but was evident when collapsed over 
the three assessment periods [Table 3 near here]. D2 receptor densities were significantly 
greater on PD 28 (eight days after conclusion of the drug pretreatment regimen) than on PD 
21 or PD 24 [Test Day main effect, F(2,27)= 4.46, p < 0.05]. D2 receptor affinity (KD) did not 
differ according to drug pretreatment regimen; however, KD values of rats tested on PD 21 
( , SEM = +.028) were significantly greater than on PD 24 ( , SEM = +.
008) or PD 28 ( , SEM = +.010) [Test Day main effect, F(2,27)= 13.09, p < 0.001].
Discussion
Although having different mechanisms of action, repeated treatment with either the partial 
D2 agonist aripiprazole or the full D2 antagonist haloperidol caused a supersensitive 
behavioral response in young rats challenged with a high dose of D-amphetamine. The 
pattern of behavioral supersensitivity varied depending on when D-amphetamine was 
administered. If assessed one day after conclusion of the drug pretreatment regimen, rats 
given aripiprazole or haloperidol exhibited both a potentiated sniffing response and an 
attenuated locomotor response after a challenge injection of D-amphetamine. If measured 
four or eight days after the drug pretreatment regimen, both aripiprazole and haloperidol 
partially attenuated the locomotor activating effects of 4 mg/kg D-amphetamine. In contrast, 
only haloperidol was able to potentiate D-amphetamine-induced stereotyped sniffing on PD 
24 and PD 28. This pattern of results suggests that repeated haloperidol treatment produced 
a more robust supersensitive response than aripiprazole. A simplistic explanation is that the 
doses of aripiprazole (10 mg/kg) and haloperidol (1 mg/kg) were not equivalent, thus 
causing haloperidol to have a more pronounced behavioral effect. Differences in D2 receptor 
affinity and intrinsic efficacy may play a more important role (Lawler et al., 1999; Burris et 
al., 2002). Alternatively, the divergent effects of aripiprazole and haloperidol may be a 
consequence of nonDA-mediated processes. For example, the partial agonist activities of 
aripiprazole at the 5-HT1A receptor may moderate or partially compensate for actions at the 
D2 receptor.
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Bordi et al. (1989) have proposed that DA-mediated behaviors are on a continuum: 
locomotor activity and rearing are induced by relatively small doses of a DA agonist (e.g., 
apomorphine or amphetamine); low- and moderate-intensity stereotypies (e.g., stereotyped 
sniffing) predominate after medium doses; and high-intensity stereotypies (e.g., vacuous oral 
movements) are observed after larger doses. Importantly, as the dose of psychostimulant 
increases “behavioral competition” can occur, in which stereotypy competes with, and 
partially masks, the locomotor response (Morelli et al., 1980; Bordi et al., 1989; Mestlin and 
McDougall, 1993). In terms of this conceptual framework, we believe that evidence for 
behavioral supersensitivity is provided by both the increased stereotyped sniffing and the 
decreased locomotion exhibited by aripiprazole- and haloperidol-pretreated rats. In some 
cases, locomotor activity was the more sensitive measure for detecting drug-induced effects. 
This was probably a consequence of stereotypy being represented by a single behavior (i.e., 
various manifestations of stereotypy competed against the locomotor response).
DA receptor up-regulation and associated neuronal changes may have been responsible for 
behavioral supersensitivity, because rats given a pretreatment regimen of aripiprazole or 
haloperidol on PD 10–20 had significantly more dorsal striatal D2 receptors than vehicle-
treated controls. Although basal levels of striatal D2 receptors increased from PD 21 to PD 
28, D2 receptor up-regulation was evident across all three test days. In contrast to these 
results, Tadokoro et al. (2012) reported that adult rats do not exhibit behavioral 
supersensitivity or D2 receptor up-regulation when tested seven days after conclusion of a 
14-day aripiprazole pretreatment regimen. Repeated haloperidol treatment, on the other 
hand, did cause both behavioral supersensitivity and D2 receptor up-regulation in adult rats 
(Tadokoro et al., 2012). A similar pattern of neurochemical effects was observed after a 21-
day drug regimen, as repeated haloperidol treatment increased dorsal striatal D2 receptor 
numbers in adult rats, while aripiprazole was without significant effect (Inoue et al., 1997). 
Interestingly, Seeman (2008) also reported that a pretreatment regimen of aripiprazole (1.5 
mg/kg/day) failed to increase D2 receptor levels in the dorsal striatum of adult rats; however, 
the percentage of receptors in the D2High state nearly doubled. The elevated number of 
D2High receptors is potentially important, because these high affinity receptors have been 
linked to DA supersensitivity (Seeman et al., 2005).
When the latter results are considered together, it appears that repeated aripiprazole 
treatment causes D2 receptor up-regulation in the dorsal striatum of young rats (present 
study), whereas a similar aripiprazole regimen does not increase D2 receptor numbers in 
adult rats (Inoue et al., 1997; Seeman, 2008; Tadokoro et al., 2012). In comparison, 
haloperidol up-regulates dorsal striatal D2 receptors in both age groups. An obvious 
possibility is that the differential actions of aripiprazole are a function of age. Needless to 
say, many dopaminergic elements (e.g., DA content, VMAT2 transporters, plasma membrane 
DA transporters) exhibit maturational changes across ontogeny (Giorgi et al., 1987; 
Broaddus and Bennett, 1990; Truong et al., 2005; Kuperstein et al., 2008). Perhaps of 
greatest relevance, dorsal striatal D1 and D2 receptor sites increase in number from birth 
through the preweanling period (Rao et al., 1991; Kuperstein et al., 2008), are dramatically 
overproduced during adolescence (Teicher et al., 1995; Andersen et al., 1997), and then 
gradually decline until adult-like levels are reached (for reviews, see Andersen and Teicher, 
2000; Andersen, 2003). To our knowledge, no systematic experiments involving multiple 
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age groups have been conducted to determine whether D2 receptor up-regulation varies 
across early ontogeny; however, it is possible that the brains of younger, still developing rats 
are more plastic than adults and, as a consequence, are more prone to aripiprazole-induced 
receptor up-regulation.
Alternatively, there are many procedural differences between these studies, hence other 
factors might be responsible for the occurrence (or nonoccurrence) of aripiprazole-induced 
receptor up-regulation. An obvious candidate is the aripiprazole dosing schedule; however, 
young rats exhibited D2 receptor up-regulation after daily injections of 10 mg/kg 
aripiprazole, whereas adult rats showed an absence of receptor up-regulation after daily 
treatments with a broad dose range (1.5–100 mg/kg) of aripiprazole (Inoue et al., 1997; 
Seeman, 2008; Tadokoro et al., 2012). Length of the drug pretreatment regimens varied 
greatly between studies but overlapped with our procedure, as we administered aripiprazole 
for 11 days, while adult rats were given aripiprazole for 7 (Seeman, 2008), 14 (Tadokoro et 
al., 2012), or 21 (Inoue et al., 1997) days. In terms of assessing DA supersensitivity, the 
biggest difference between studies was that we measured locomotor activity and stereotypy 
after challenge injections of either a moderate or high dose of D-amphetamine, whereas 
Tadokoro et al. (2012) assessed locomotor activity after treatment with a relatively low dose 
of methamphetamine (1 mg/kg). In our study, behavioral supersensitivity was most 
prominent when a high dose of D-amphetamine (4 mg/kg) was administered. Considering 
the latter result, it remains possible that aripiprazole-pretreated adult rats might exhibit a 
supersensitive behavioral response if stereotyped behaviors were assessed and a high dose of 
psychostimulant was administered on the test day.
In the present study, various stereotyped behaviors were quantified and it was apparent that 
sniffing was the predominant form of stereotypy. Young rats and mice typically exhibit less 
intense stereotypies than adults (Adriani and Laviola, 2000; but see Abrams and Bruno, 
1992), with stereotyped sniffing rather than vacuous oral movements predominating in 
young rats given high-dose DA agonist treatment (e.g., Charntikov et al., 2008, 2011; Cortez 
et al., 2010). A different pattern of effects was evident when behavior was assessed one day 
after conclusion of the drug pretreatment regimen (i.e., on PD 21). Specifically, aripiprazole- 
and haloperidol-pretreated rats exhibited substantial amounts of stereotyped licking (a 
vacuous oral movement) when challenged with 4 mg/kg D-amphetamine (data not shown). 
Stereotyped licking was not observed in vehicle-treated rats or when testing occurred four or 
eight days after conclusion of the drug pretreatment regimen. Thus, it appears that the most 
intense stereotypy occurred one day after the final haloperidol or aripiprazole injection.
When assessed one or four days after conclusion of the drug pretreatment regimen, both 
aripiprazole and haloperidol significantly reduced the body weight gain of our male and 
female rats (similar trends were reported in a previous study; Der-Ghazarian et al., 2012). 
Unfortunately, studies involving adult rats provide inconsistent results, because repeated 
haloperidol treatment (3–12 weeks) has been reported to reduce (von Wilmsdorff et al., 
2010, 2013), not affect (Minet-Ringuet et al., 2005; Lin et al., 2006; Han et al., 2008), or 
enhance (Fell et al., 2004, 2005) body weight gain. In the latter case, females were more 
likely than males to exhibit haloperidol-induced weight gain (Baptista et al., 1987; Pouzet et 
al., 2003). Although studied less intensively, long-term treatment with a high dose of 
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aripiprazole (40 mg/kg) may cause a relative decline in the body weights of adult rats 
(Segnitz et al., 2009), while a 12-week exposure to a low dose of aripiprazole (2.25 mg/kg) 
was without effect (Han et al., 2008). The reason why aripiprazole and haloperidol 
decreased the body weights of our young rats is uncertain, but it could be a consequence of 
elevated levels of circulating insulin (Lin et al., 2006; von Wilmsdorff et al., 2013). It is also 
possible that the drugs interfered with the ability to suckle, since body weight differences 
between the aripiprazole and vehicle groups were apparent by PD 13 (data not shown).
In clinical terms, adult humans respond well to aripiprazole, as it has an excellent side-effect 
profile (for reviews, see Stip and Tourjman, 2010; Croxtall, 2012). Even so, the response of 
younger patients to any pharmacotherapy cannot be deduced from observing adults, 
especially since children and adolescents are more prone to tolerability issues (Correll and 
Carlson, 2006). Moreover, safety concerns increase in prominence if drugs are prescribed for 
long durations (Fraguas et al., 2011), and available evidence suggests that children and 
adolescents are typically maintained on second-generation antipsychotics for 30 months or 
more (Kalverdijk et al., 2008). All of that being said, there are enough studies involving 
pediatric populations to tentatively conclude that aripiprazole has a good side-effect profile 
in younger age groups as well as adults (Greenaway and Elbe, 2009; Doey, 2012; Kirino, 
2012; but see Rugino and Janvier, 2005; Fraguas et al., 2011; McKinney and Renk, 2011). 
When compared to second-generation antipsychotics, aripiprazole causes less weight gain in 
children, less sedation, and does not increase serum prolactin levels (Ardizzone et al., 2010; 
Fraguas et al., 2011; Zuddas et al., 2011). Neuromotor side-effects are more problematic. 
Although superior to first-generation antipsychotics (e.g., haloperidol), aripiprazole is prone 
to akathisia and extrapyramidal symptoms, such as tremor and Parkinsonism (Findling et al., 
2008, 2009b; Zuddas et al., 2011). Not surprisingly, higher doses (e.g., 30 mg/day) of 
aripiprazole are more likely to produce neuromotor side-effects in children and adolescents 
than are lower doses (10 mg/day) (Findling et al., 2008, 2009b; Ardizzone et al., 2010).
With regard to translational relevance, the dose of aripiprazole used in the present study (10 
mg/kg/day) is substantially greater than the dose range typically administered to children 
and adolescents (10–30 mg/day). These dosing parameters can be explained by drug 
metabolism pharmacokinetics, as the elimination half-life of aripiprazole is approximately 
47–75 hr in humans (Mallikaarjun et al., 2004; Greenaway and Elbe, 2009) and 1.9–2.2 hr in 
rats (Shimokawa et al., 2005). When coupled with the different lengths of drug exposure 
(days for young rats vs. months to years for young humans), it is possible that the 
aripiprazole- and haloperidol-induced neural changes reported in the present study 
conservatively reflect receptor alterations that might be occurring in children and 
adolescents. As mentioned above, aripiprazole has a good side-effect profile, although 
younger patients may exhibit mild-to-moderate extrapyramidal symptoms and akathisia. 
Based on the present results, it is possible that some of these motoric effects may be a 
consequence of DA supersensitivity and associated D2 receptor changes in the dorsal 
striatum (for further discussion, see Schröder et al., 1998; Tenback et al., 2010).
In terms of limitations and constraining factors, the most notable issue is that only a single 
dose of aripiprazole was used and neither serum nor brain levels of this compound were 
determined. Aripiprazole doses ranging from 10–12 mg/kg are commonly administered to 
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rodents (Semba et al., 1995; Li et al., 2005; Cheng et al., 2008; Segnitz et al., 2009), but a 
broader dose range would have made interpretation easier. The overarching purpose of this 
study was to determine whether administering aripiprazole to young rats would cause D2 
receptor up-regulation and DA supersensitivity. Because rodent development is so rapid (for 
a review, see Andersen, 2003), the drug pretreatment regimen was necessarily short (11 
days). To test the same experimental hypotheses using a substantially longer pretreatment 
regimen would require a species with a more prolonged developmental trajectory. It is also 
important to recognize that we used “normal” rats and not an animal model designed to 
mimic one or more aspects of a human disorder (for the advantages and disadvantages of 
using these animal models, see Lipska and Weinberger, 2000; McGonigle, 2013). This 
decision was partially based on the realization that aripiprazole is used to treat a wide variety 
of developmental disorders (e.g., bipolar I disorder, schizophrenia, autism and other 
pervasive developmental disorders, aggression, conduct disorder, Tourette’s syndrome and 
chronic tic disorder); thus, the use of a standard rat strain was considered appropriate for this 
exploratory study. Lastly, since aripiprazole affects DA functioning, as well as serotonergic, 
GABAergic, and glutamatergic systems, future research should be aimed at parsing out 
whether nondopaminergic systems interact with DA systems to mediate or influence 
aripiprazole-induced behavioral supersensitivity and D2 receptor up-regulation.
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Figure 1. 
Mean distance traveled (±SEM) of saline- and amphetamine-treated rats tested on postnatal 
day (PD) 21 (i.e., one day after conclusion of the drug pretreatment regimen). Rats had been 
pretreated with vehicle, 10 mg/kg aripiprazole, or 1 mg/kg haloperidol on PD 10–20. The 
testing session lasted 120 min (divided into six 20-min time blocks).
* Significant difference between the vehicle and haloperidol group on the same time block.
† Significant difference between the vehicle and aripiprazole group on the same time block.
‡ Significantly different from the vehicle group when collapsed across time blocks 1–6.
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Figure 2. 
Mean distance traveled (±SEM) of saline- and amphetamine-treated rats tested on postnatal 
day (PD) 24 (i.e., four days after conclusion of the drug pretreatment regimen). Rats had 
been pretreated with vehicle, 10 mg/kg aripiprazole, or 1 mg/kg haloperidol on PD 10–20. 
The testing session lasted 120 min (divided into six 20-min time blocks).
* Significant difference between the vehicle and haloperidol group on the same time block.
† Significant difference between the vehicle and aripiprazole group on the same time block.
‡ Significantly different from the vehicle group when collapsed across time blocks 1–6.
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Figure 3. 
Mean distance traveled (±SEM) of saline- and amphetamine-treated rats tested on postnatal 
day (PD) 28 (i.e., eight days after conclusion of the drug pretreatment regimen). Rats had 
been pretreated with vehicle, 10 mg/kg aripiprazole, or 1 mg/kg haloperidol on PD 10–20. 
The testing session lasted 120 min (divided into six 20-min time blocks).
* Significant difference between the vehicle and haloperidol group on the same time block.
† Significant difference between the vehicle and aripiprazole group on the same time block.
‡ Significantly different from the vehicle group when collapsed across time blocks 1–6.
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Figure 4. 
Mean sniffing counts (±SEM) of saline- and amphetamine-treated rats tested on postnatal 
day (PD) 21 (i.e., one day after conclusion of the drug pretreatment regimen). These are the 
same rats as described in Figure 1.
‡ Significantly different from the vehicle group when collapsed across time blocks 1–6 
(Pretreatment Condition main effect, p < 0.05).
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Figure 5. 
Mean sniffing counts (±SEM) of saline- and amphetamine-treated rats tested on postnatal 
day (PD) 24 (i.e., four days after conclusion of the drug pretreatment regimen). These are 
the same rats as described in Figure 2.
‡ Significantly different from the vehicle group when collapsed across time blocks 1–6 
(Pretreatment Condition main effect, p < 0.05).
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Figure 6. 
Mean sniffing counts (±SEM) of saline- and amphetamine-treated rats tested on postnatal 
day (PD) 28 (i.e., eight days after conclusion of the drug pretreatment regimen). These are 
the same rats as described in Figure 3.
‡ Significantly different from the vehicle group when collapsed across time blocks 1–6 
(Pretreatment Condition × Test Drug interaction, p < 0.05).
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Table 1
Effects of repeated aripiprazole treatment on D2 receptor densities in the dorsal striatum of adult rats
Author and year of 
publication Rat strain Dose and Route of administration Duration Effects
Inoue et al., 1997 Wistar 12 or 100 mg/kg/day, oral 21 days Nonsignificant D2 receptor up-
regulation
Seeman, 2008 Sprague-Dawley 1.5 mg/kg/day, subcutaneous 7 days No D2 receptor up-regulation
Increased percentage of D2High 
receptors
Tadokoro et al., 2012 Sprague-Dawley 1.5 mg/kg/day, minipump 14 days No D2 receptor up-regulation
No DA supersensitivity
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Table 3
Mean D2 receptor densities of young rats (n = 10 per group) measured one, four, or eight days after conclusion 
of the drug pretreatment regimen that occurred on PD 10–20. Bmax values are expressed as fmol/mg protein 
(+SEM).
Drug Pretreatment Days After Pretreatment Regimen
One Four Eight
Vehicle 255.34 (+31.6) 235.11 (+20.5) 350.51 (+23.1) 280.32 (+17.0)
Aripiprazole (10 mg/kg) 334.39 (+33.4) 298.56 (+30.1) 370.35 (+26.5) 334.43 (+17.7)*
Haloperidol (1 mg/kg) 326.11 (+30.1) 320.73 (+36.2) 398.16 (+22.0) 348.33 (+18.0)*
*Significantly different from the vehicle group.
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